Germany Adjusts Amid BioNTech Vaccine Production Shift

The German government has announced that the loss of BioNTech vaccine production can be offset by other companies. Despite BioNTech closing sites and affecting jobs due to a strategic pivot, the government assures that vaccine supply remains secure.

The German government on Wednesday expressed confidence that the country's vaccine supply remains secure despite BioNTech's decision to close several production sites.

A government spokesperson confirmed that other companies are slated to compensate for the production shortfall as BioNTech shifts focus from pandemic-specific manufacturing.

BioNTech’s recent announcement affects up to 1,860 jobs amid its strategic pivot away from COVID-19 vaccine production.